Vol.70 No.1 January 2022
Analysis of the incidence of adverse reactions and of the IgG antibody titers after vaccination for SARS-CoV-2
1)Department of Pharmacy, Hirakata Kosai Hospital, 1-2-1 Fujisaka Higashimachi, Hirakata, Osaka, Japan
2)Department of Infection Control and Prevention, Hirakata Kosai Hospital
3)Department of Clinical Laboratory Medicine, Hirakata Kosai Hospital
4)Department of Pulmonology, Hirakata Kosai Hospital
5)Department of Endocrinology and Metabolism, Hirakata Kosai Hospital
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of coronavirus disease 2019 (COVID-19), was declared a worldwide pandemic at the beginning of 2020 and continues to have a dramatic impact on society as of 2021. Approval for the first vaccine against COVID-19 was obtained in early 2021, and at present, improvement in the rate of vaccination of the world population remains an urgent focus, along with determination of the efficacy and safety of the vaccine. In this study, we evaluated the efficacy and safety of COVID-19 vaccination by investigating the adverse reactions and measuring the IgG antibody titers of staff who had received the vaccination.
The testing for the IgG antibodies was performed using reagents from "Abbott SARS-CoV-2 IgG II Quant", and a questionnaire survey was conducted on April 09, 2021 to determine the incidence/nature of adverse reactions to the vaccination in 433 employees of the Federation of National Public Service Personnel Mutual Aid Associations Hirakata Kosai Hospital who had received 2 doses of the COMIRNATY vaccine. The incidence of fatigue, headache, arthralgia, chills, and fever (>37.5°C) were significantly higher after the second dose as compared to that after the first dose (p<0.001). Moreover, the manifestation rates of adverse reactions were significantly higher in younger people (p<0.05). For example, the incidence of fever was 40.3% after the second dose (12.6 times that after the first dose) and 54.0% in people who were in their 20s (4.3 times that in people aged 60 years old or over). The rate of consumption of antipyretic analgesics was 59.7% (4.1 times that after the first dose), and the rate of absenteeism due to various adverse reactions was 25.2% (6.3 times that after the first dose). Antibody titers were elevated in all subjects, but were significantly higher in younger people (p<0.005). Furthermore, among people aged >30 years old, the titers were significantly higher in women than in men (p<0.01). With the increase in the rates of vaccination of the population, it is believed that the impacts of adverse reactions on daily life in younger subjects will become more and more apparent. Therefore, it is important to understand and estimate the incidence rates of adverse reactions in advance.
Key word
SARS-CoV-2, mRNA vaccine, side effect, antibody titer
Received
August 2, 2021
Accepted
November 12, 2021
Jpn. J. Chemother. 70 (1): 73-79, 2022
